What is Batavia Biosciences?
Founded in 2010 and headquartered in the Netherlands, Batavia Biosciences operates as a contract development and manufacturing organization (CDMO). The company specializes in the development of vaccines, monoclonal antibodies, and recombinant proteins, positioning itself as a key player in supporting the biopharmaceutical industry's pipeline. Its focus on complex biologics addresses critical needs in therapeutic and preventative medicine development.
How much funding has Batavia Biosciences raised?
Batavia Biosciences has raised a total of $8M across 1 funding round:
Grant
$8M
Grant (2016): $8M with participation from Bill & Melinda Gates Foundation
Key Investors in Batavia Biosciences
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation, established in 2000, is a global organization dedicated to improving health and reducing poverty. Its focus on health initiatives aligns with Batavia Biosciences' work in vaccine and therapeutic development.
What's next for Batavia Biosciences?
The enterprise-level funding context suggests Batavia Biosciences is poised for significant scaling and expansion of its development and manufacturing capabilities. This strategic investment will likely fuel advancements in its specialized services, potentially enabling the company to take on larger projects, enhance its technological infrastructure, and broaden its market reach within the global biopharmaceutical landscape. The company's trajectory indicates a strong emphasis on growth and innovation in its specialized CDMO services.
See full Batavia Biosciences company page
